UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) September 18, 2008

PRESSURE BIOSCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) **MASSACHUSETTS** (State or Other Jurisdiction of Incorporation) 0-21615 04-2652826 (Commission File Number) (IRS Employer Identification No.) 14 Norfolk Avenue, South Easton, MA 02375 (Address of Principal Executive Offices) (Zip Code) (508) 230-1828 (Registrant's Telephone Number, Including Area Code) N/A (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): [] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Information

On September 18, 2008, Pressure BioSciences, Inc. (the "Company") submitted a purchase order to Source Scientific, LLC, the manufacturer of the Company's PCT Barocycler instrumentation, for 50 Barocycler NEP2320 units. Pursuant to the terms of the purchase order, the Company placed a deposit with Source Scientific, LLC, of approximately \$100,000, representing approximately 25% of the expected total value of the order. The Company will place an additional deposit of approximately \$100,000 with Source Scientific, LLC, upon their commencement of the manufacture of the units, expected to be early in the fourth quarter of 2008. The purchase price for the 50 Barocycler NEP2320 units is based upon a fixed bill of materials. The Company expects that the NEP2320 units will be completed and ready for sale to its customers during the first quarter of 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: September 19, 2008 PRESSURE BIOSCIENCES, INC.

By: <u>/s/ Edward H. Myles</u>
Edward H. Myles, Senior Vice President of Finance and Chief Financial Officer